Browsing by Author "Marselos, M."
Now showing items 1-4 of 4
-
Article
Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer
Briassoulis, E. Ch; Pappas, P.; Puozzo, C.; Ch, F. Tolis; Fountzilas, George; Dafni, U.; Marselos, M.; Pavlidis, Nicholas (2009)Aim: To determine the safe dose range and pharmacokinetics of metronomic oral vinorelbine and obtain preliminary data on biomarkers and efficacy in patients with advanced cancer. Methods: Successive cohorts ofpatients ...
-
Article
Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): A study of 100 CUP cases
Golfinopoulos, Vassilis; Pentheroudakis, George; Goussia, Anna; Siozopoulou, V.; Bobos, M.; Krikelis, D.; Cervantes, A.; Ciuleanu, T.; Marselos, M.; Fountzilas, George; Malamou-Mitsi, Vassiliki D.; Pavlidis, Nicholas (2012)Background: Hypothesising that cancer of unknown primary (CUP) may harbour unique characteristics, we present a translational study of the immunohistochemical expression and clinical correlation of key PTEN/AKT pathway ...
-
Article
Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study
Pappas, P.; Karavasilis, V.; Briassoulis, E. Ch; Pavlidis, Nicholas; Marselos, M. (2005)Aim: To evaluate the pharmacokinetics of imatinib mesylate (Glivec) and its main metabolite (CGP74588) in a patient with end stage renal disease on hemodialysis and compare it with published data from subjects with normal ...
-
Article
Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy
Pentheroudakis, George; Pappas, P.; Golfinopoulos, Vassilis; Fountzilas, George; Nikolaidou, M.; Boumba, V. A.; Vougiouklakis, T.; Nikiforidis, L.; Tzamakou, E.; Siarabi, O.; Marselos, M.; Pavlidis, Nicholas (2007)Background: Although protracted intravenous 5-fluorouracil is superior to bolus regimens in terms of tumour exposure to the drug during DNA synthesis as well as activity and safety, the oral fluoropyrimidine capecitabine ...